BiotechTube
Grace Science

Grace Science

San Diego, United States· Est.
gracescience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $40M

Overview

Grace Science is a private, pre-clinical stage biotech leveraging a decade of proprietary research on the NGLY1 pathway to develop novel therapeutics. The company's pipeline includes a lead gene therapy program for the ultra-rare NGLY1 Deficiency and exploratory small molecule programs targeting broader indications in cancer and neurodegenerative diseases. With a world-class scientific foundation, notable co-founders including a Nobel Laureate, and a strategic collaboration with Takeda, Grace Science aims to validate NGLY1 as a pivotal therapeutic target with potential impact across multiple disease areas.

Rare Genetic DiseaseOncologyNeurodegenerative Diseases

Technology Platform

A proprietary biological insight platform centered on the N-glycanase 1 (NGLY1) pathway, a conserved gene critical for cellular quality control. The platform leverages deep understanding of this pathway to identify novel targets and develop therapies across modalities (gene therapy, small molecules) for diseases linked to NGLY1 dysfunction.

Funding History

1
Total raised:$40M
Series A$40M

Opportunities

The primary opportunity is to establish NGLY1 as a validated, novel therapeutic target, first through a gene therapy cure for an ultra-rare disease (enabling orphan drug incentives and rapid proof-of-concept), and then by leveraging that validation to develop small molecule drugs for massive markets in oncology and neurodegeneration.
A successful partnership with Takeda provides credibility, resources, and a potential path to commercialization.

Risk Factors

The core scientific hypothesis that NGLY1 modulation is therapeutic remains unproven in humans, creating high clinical risk.
The company's entire platform and pipeline are concentrated on a single gene target, creating binary success/failure risk.
As a pre-revenue company, it faces significant financial risk and dilution from the high costs of advancing gene and small molecule therapies.

Competitive Landscape

For NGLY1 Deficiency, competition is minimal due to the ultra-rare nature of the disease. However, in the broader target markets of oncology and neurodegeneration, Grace Science will face intense competition from large pharmaceutical companies and numerous biotechs pursuing a wide array of mechanisms. Its competitive edge lies in its deep, proprietary foundational biology and first-mover advantage in targeting the NGLY1 pathway.

More companies in Rare & Orphan Diseases →More companies in United States →